Novavax Quarterly Balance Sheet
NASDAQ: NVAXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 12.69 -0.47%
Novavax financial position
As of Jun 30, 2026, Novavax reported total assets of $955.6 million, down 28.5% from a year earlier against total liabilities of $1.15 billion. Shareholders' equity was negative at -$190.7 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $191.5 million in cash and equivalents against $291.5 million of debt, a net debt position of $100.0 million.
The current ratio (current assets divided by current liabilities) was 2.33, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Novavax balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 191.46M | 228.36M | 240.63M | 268.02M | 253.74M | 263.34M | 530.23M | 573.63M | 680.16M | 480.59M | 568.50M | 651.10M |
| Short-Term Investments | 527.88M | 561.97M | 494.45M | 494.87M | 358.56M | 468.14M | 392.89M | 335.90M | 369.43M | — | 0 | — |
| Inventory | 10.01M | 11.46M | 11.54M | 13.51M | 10.24M | 10.26M | 8.75M | 8.64M | 9.17M | 15.78M | 41.70M | 69.59M |
| Total Current Assets | 771.10M | 850.82M | 978.28M | 974.59M | 919.51M | 868.03M | 1.13B | 1.10B | 1.20B | 727.12M | 1.14B | 1.01B |
| Property, Plant & Equipment | 38.13M | 42.15M | 44.80M | 49.12M | 129.64M | 133.54M | 138.41M | 285.72M | 288.56M | 291.09M | 305.77M | 300.98M |
| Goodwill | 112.54M | 112.89M | 113.46M | 113.08M | 112.96M | 112.03M | 107.48M | 126.77M | 123.38M | 123.18M | 127.45M | 123.78M |
| Total Assets | 955.58M | 1.04B | 1.18B | 1.18B | 1.34B | 1.29B | 1.56B | 1.71B | 1.82B | 1.35B | 1.80B | 1.66B |
| Accounts Payable | 22.94M | 16.10M | 24.58M | 15.23M | 50.59M | 34.16M | 41.58M | 57.52M | 79.96M | 57.72M | 132.61M | 101.91M |
| Total Current Liabilities | 330.57M | 342.46M | 459.95M | 429.87M | 389.14M | 422.17M | 1.15B | 1.18B | 1.16B | 804.38M | 1.64B | 1.47B |
| Long-Term Debt | 291.49M | 291.04M | 244.21M | — | — | — | — | — | — | — | — | — |
| Total Liabilities | 1.15B | 1.19B | 1.30B | 1.34B | 1.30B | 1.37B | 2.18B | 2.24B | 2.25B | 2.22B | 2.51B | 2.34B |
| Shareholders' Equity | -190.71M | -144.76M | -127.75M | -156.67M | 37.63M | -75.64M | -623.84M | -526.44M | -431.71M | -867.08M | -716.93M | -678.35M |
| Retained Earnings | -4.63B | -4.58B | -4.57B | -4.59B | -4.38B | -4.49B | -5.01B | -4.93B | -4.81B | -4.97B | -4.82B | -4.64B |
| Total Debt | 291.49M | 291.04M | 244.21M | — | — | — | — | — | — | — | — | — |
| Net Cash (Debt) | 427.85M | 499.29M | 490.87M | 762.89M | 612.30M | 731.48M | 923.12M | 909.53M | 1.05B | 480.59M | 568.50M | 651.10M |
| Shares Outstanding | 164.82M | 164.42M | 162.58M | 162.47M | 162.16M | 161.96M | 160.42M | 160.15M | 159.89M | 140.37M | 139.51M | 118.73M |
This table shows 12 quarterly periods of Novavax's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow NVAX's reporting calendar. What is a balance sheet?